Welcome to our dedicated page for PETMED EXPRESS SEC filings (Ticker: PETS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PetMed Express, Inc. filings document the regulatory record for a Florida public company operating the PetMeds and PetCareRx pet pharmacy businesses. Annual and current reports disclose operating results, non-GAAP reconciliations, intangible-asset impairment matters involving the PCRX trade name, and the financial reporting issues reflected in Forms 12b-25 and Nasdaq continued-listing notices.
Other filings cover governance and capital-structure matters, including annual meeting voting results, director elections, executive compensation advisory votes, audit committee composition, amendments to the shareholder rights agreement, and modifications to security holder rights. The record also includes Form 8-K disclosures for material agreements, board appointments, results releases, and listing compliance communications.
Campbell Leslie C.G. reported acquisition or exercise transactions in this Form 4 filing.
PETMED EXPRESS INC reported that Interim CEO and President Leslie C.G. Campbell received a grant of 60,000 shares of Common Stock as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan on 2026-08-11. The award vests in full on the first anniversary of the grant date, subject to continued employment and possible accelerated vesting upon death, disability, a change of control, or certain terminations of employment. Following this grant, Campbell directly holds 145,000 shares of Common Stock. An additional 30,000 shares are held in the Leslie C.G. Campbell 2020 Irrevocable Trust for family members; Campbell is not a beneficiary and disclaims beneficial ownership of those trust shares.
PetMed Express, Inc. reported for the quarter ended June 30, 2026 net sales of $41.0 million, down 19.9% from a year earlier, driven mainly by lower prescription medication sales and reduced marketing spend. Gross margin slipped to 27.6%, and the company posted a net loss of $6.1 million, or $(0.28) per share, versus a prior-year loss of $34.2 million that included large impairment charges. Adjusted EBITDA was a loss of $3.4 million. Cash and cash equivalents declined to $13.1 million, with a working capital deficit as current liabilities exceeded current assets by about $13.0 million. Management identified conditions that initially raised substantial doubt about continuing as a going concern but concluded this doubt is alleviated based on planned cost and capex reductions. Subsequent to quarter-end, the company agreed to a $37.0 million sale-leaseback of its Delray Beach headquarters and distribution center and is reviewing a public, unsolicited, non-binding cash acquisition proposal at $3.00 per share from SilverCape Investments Limited.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of common stock of PETMED EXPRESS INC. The filing states that they collectively beneficially own 1,131,230 shares of common stock, representing 5.29% of the outstanding class as of June 30, 2026.
The reporting persons have sole voting power and sole dispositive power over all 1,131,230 shares, with no shared voting or dispositive power. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and proceeds from the sale of these securities.
PetMed Express reported first quarter results for the period ended June 30, 2026. Net sales were $41.0 million, down 19.9% from $51.2 million a year earlier as lower consumer promotional usage was more than offset by weaker prescription medication sales. Net loss was $6.1 million, or $(0.28) per diluted share, a substantial improvement from a $34.2 million loss, or $(1.65) per share, primarily due to the absence of prior-year goodwill and trade name impairment charges and lower general and administrative and advertising expenses, partially offset by lower gross profit.
Adjusted EBITDA was $(3.4) million, compared with $(2.7) million in the prior-year quarter, reflecting a $0.8 million decline. Operating cash use improved but remained negative, with net cash used in operating activities of $7.7 million versus $12.3 million a year earlier. Cash and cash equivalents were $13.1 million at June 30, 2026, down from $21.4 million at March 31, 2026. Management highlighted more efficient marketing with 70,000 new customers and a 15% lower acquisition cost, nearly 14% lower general and administrative expenses, completion of an SAP ERP rollout, and a recently announced sale-leaseback intended to strengthen the balance sheet.
PetMed Express, Inc. reported results of its 2026 Annual Meeting of Shareholders and an amendment to its equity compensation plan. Shareholders approved a 2026 Plan Amendment to the PetMed Express, Inc. 2024 Omnibus Incentive Plan, increasing the shares of common stock reserved for issuance under the plan by 1,800,000 shares.
As of the June 15, 2026 record date, 21,371,880 voting shares were outstanding, and 14,291,482 shares were represented in person or by proxy, constituting a quorum. Four director nominees were elected, shareholders approved on an advisory basis the compensation of named executive officers, ratified Baker Tilly US, LLP as independent registered public accounting firm for fiscal year 2026, and approved the amendment to the 2024 Omnibus Incentive Plan.
LaCamp James reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express IncJames LaCamp55,555 sharesAugust 11, 202790,421 shares
Batushansky Peter reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express Inc. director Peter Batushansky reported a grant of 55,555 shares of common stock as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan. The award vests in full on August 11, 2027, subject to his continued service on the Board of Directors, bringing his direct holdings to 91,928 shares.
Mennen Justin L. reported acquisition or exercise transactions in this Form 4 filing.
PetMed Express Inc. director Justin L. Mennen received a grant of 55,555 shares of Common Stock as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan. These shares vest in full on August 11, 2027, subject to his continued service on the Board of Directors.
After this award, Mennen directly holds 98,274 shares of PetMed Express common stock.
KRULIK DOUGLAS reported acquisition or exercise transactions in this Form 4 filing.
PETMED EXPRESS INC reported equity awards to CAO and Interim CFO Douglas Krulik effective June 26, 2026. He received 32,500 restricted common shares that vest 50% on June 26, 2027 and 50% on June 26, 2028, plus 32,500 performance share units tied to total shareholder return from April 1, 2026 to March 31, 2028.
The amended insider report corrects the PSUs’ performance period description and aligns their March 31, 2028 expiration date; it states no other changes. Following the restricted stock grant, Krulik directly holds 102,500 common shares.
PetMed Express, through its wholly owned subsidiary 420 South Congress Avenue, LLC, has agreed to a sale-leaseback of its Delray Beach, Florida headquarters and related property with Redfearn Capital Acquisitions, LLC for an aggregate purchase price of $37.0 million. The buyer will place a $0.5 million initial deposit and an additional $1.7 million deposit after a Due Diligence Period of up to 30 days, which may be extended by up to 45 days, with closing 30 days after that period, subject to customary conditions and completion of lease negotiations.
At closing, PetMed Express is expected to enter into a 120‑month, triple‑net lease for 100,519 square feet at 420 South Congress Avenue, with first‑year base rent of $15.25 per square foot and 3.5% annual increases. The lease will include three consecutive five‑year extension options at fair‑market‑value starting rents, a cap on property management fees at 4% of gross rent, and requirements to prepay the third year of base rent and provide a security deposit equal to one year’s rent. The company anticipates completing the transaction within 120 days and describes monetizing its real estate as part of its efforts to strengthen its balance sheet, focus on its core pharmacy business, and retain long‑term use of its current headquarters.